Neoplasms

All Conditions

Rare Diseases

Carcinoma

Carcinoma, Transitional Cell

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Transitional Cell Carcinoma

Antineoplastic Agents

All Drugs and Chemicals

Pembrolizumab

Immunomodulating Agents

Matteo Santoni, MD, PhD

Giulia Sorgentoni

Giulia Sorgentoni, PhD

The ARON-2 study retrospectively analyze patients treated with pembrolizumab as first-line therapy in patients platinum-unfit or as second-line therapy in patients progressed after previous platinum-based chemotherapy. The amendment has been designed to also analyze patients treated with enfortumab vedotin progressed to previous platinum-based chemotherapy and anti-PD-1/PD-L1 inhibitor.

ARON-2 Study-Multicentric International Retrospective Study

Statistical analysis of data obtained by medical charts related to smoking attitude, obesity and concomitant medications in patients with metastatic UC treated with pembrolizumab or enfortumab vedotin

Matteo Santoni

Oncologist

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Carcinoma, Renal Cell

Adenocarcinoma

Kidney Neoplasms

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Diseases

Urologic Diseases

Male Urogenital Diseases

Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

Lenvatinib

Bevacizumab

Avelumab

Axitinib

Nivolumab

Atezolizumab

Ipilimumab

Antineoplastic Agents, Immunological

Immune Checkpoint Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

collect global experiences with the use of immuno-combinations in patients with metastatic RCC

pembrolizumab plus axitinib

The ARON-1 Study is designed as an International Multicentric Retrospective Study to collect global experiences with the use of immuno-combinations in patients with metastatic RCC.

Two Supplementary Studies (ARON-1α and ARON-1β) have been designed. The ARON-1α Supplementary Study has been designed to investigate for the presence of genomic signatures from tumor samples of patients treated with first-line immuno-combinations for advanced RCC. The ARON-1β Supplementary Study has been designed to charaterize the immune cell populations and assess their relationship with the clinical outcome of mRCC patients treated with first-line immuno-combinations

International Multicentric Study ARON-1

Data on tumor assessment and response to therapy on elderly populaton will be statistically analyzed

Data on tumor assessment and response to therapy will be statistically analyzed

Statistical analysis of prognostic role of smoking attitude and obesity in treated RCC patients

Data on tumor assessment and response to therapy in non-clear RCC will be statistically analyzed

Hospital of Macerata

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
ARON-2 Study-Multicentric International Retrospective Study	NCT05290038	Urothelial Carc...		18 Years -	Hospital of Macerata
ARON-2 Study-Multicentric International Retrospective Study	NCT05290038	Urothelial Carc...		18 Years -	Hospital of Macerata
International Multicentric Study ARON-1	NCT05287464	Metastatic Rena...	pembrolizumab p...	18 Years -	Hospital of Macerata
ARON-2 Study-Multicentric International Retrospective Study	NCT05290038	Urothelial Carc...		18 Years -	Hospital of Macerata

Spots Global Cancer Trial Database for artificial intelligence technology